Takeda Pharmaceutical Ceases Diabetes Therapy Development (Japan)
This article was originally published in PharmAsia News
Takeda Pharmaceutical in Japan has ceased development of diabetes therapy combining Actos with TAX-536, an angiotensin receptor blocker, because they do not mix well. (Click here for more
You may also be interested in...
ODAC's 17-18 June discussion of pediatric development plans for four investigational oncology agents will serve as a trial run of the technology platform and logistics for any future application-specific virtual advisory committee meeting, but without the stress associated with a pending application and a user fee deadline.
Vibostolimab is less advanced than Roche’s competing tiragolumab, but Merck thinks the combo of its anti-TIGIT and Keytruda will offer a better therapeutic profile.
Ambitious efforts to make the EU more resilient to future challenges, such as health threats, drug supply problems, scientific advances and growing medicine costs, have taken a step forward with the publication of a roadmap for a wide-ranging Pharmaceutical Strategy to be adopted by the European Commission later in the year.